Stanley D. Rose, Ph.D.
Senior Fellow, Council on Strategic Risks
Dr. Stan Rose is a Senior Fellow at the Council on Strategic Risks, contributing to CSR’s Alliance to End Biological Threats. He is a Ph.D. biologist, life sciences executive, and serial entrepreneur. He has spent over three decades working with leading scientists and clinicians to create substantial commercial value from inventions based on genome analysis technology. Since 2008 Dr. Rose has served as President of Rose Ventures, a firm engaged in consulting, directing, and investing in the life sciences. Dr. Rose was co-founder, President and CEO of Transplant Genomics Inc. (acquired by Eurofins in 2019), whose TruGraf® blood gene expression tests are used in the care of kidney transplant recipients. He continues to serve as Executive Chairman of Eurofins-TGI. Dr. Rose also serves on the Board of Invenra, a biotechnology company focused on the discovery and development of multi-specific antibodies for immuno-oncology.
Dr. Rose was a Director of Cellular Dynamic International (NASDAQ: ICEL), a leader in pluripotent stem cell technology for drug discovery and cell therapy (acquired by FujiFilm in 2015), and Chair of the Market Advisory Board for Cyvek, a protein immunoassay and immunodiagnostics company acquired by Bio-Techne in 2014. Highlights from earlier in his career include serving as CEO of NimbleGen Systems, a genomics tools company acquired by Roche in 2007; co-founding and growing Genetic MicroSystems, a microarray instrumentation company that was acquired by Affymetrix in 2000; and directing the PCR business for Perkin-Elmer and Applied Biosystems during its most dynamic growth phase in the 1990s.
Dr. Rose received his B.A. from Cornell University and his Ph.D. from the Massachusetts Institute of Technology.